Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Enveda, a biotech startup utilizing AI to discover drugs from natural sources, has raised $311 million in a Series E funding round. The investment values the company at $2 billion, doubling its valuation from the previous year. The funds will support the advancement of several AI-discovered drug candidates into human clinical trials.
- ▪Enveda secured a $311 million Series E round led by Catalio Capital Management with participation from Iconiq.
- ▪The company achieved a $2 billion valuation, which is double the amount reached twelve months prior.
- ▪Enveda was founded in 2019 by Viswa Colluru to use AI for discovering medicines from plants and microbes.
- ▪The startup is currently testing drugs for severe skin conditions and weight maintenance after stopping GLP-1s.
TechCrunch files mainly under tech. We currently carry 1,013 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | TechCrunch |
| Canonical URL | https://techcrunch.com/2026/09/23/enveda-secures-311m-to-bring-more-nature-derived-ai-drugs-into-clinical-trials/ |
| Publication time | Wed, 23 Sep 2026 19:31:28 +0000 |
| Retrieval time | 2026-09-23T19:34:30.846Z |
| Last seen | 2026-09-23T19:34:30.846Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | lCLDvA_goO5c · 1 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
In Brief Posted: 12:31 PM PDT · September 23, 2026 Image Credits:Viswa Colluru / Enveda Marina Temkin Enveda secures $311M to bring more nature-derived AI drugs into clinical trials Enveda, a biotech startup that uses AI to discover new drugs in the natural world, has raised a $311 million Series E at a $2 billion valuation. The fresh funding, which was led by Catalio Capital Management, with participation from Iconiq and others, doubles the valuation Enveda achieved 12 months ago. The idea behind Enveda is that powerful medicines could be harnessed from plants and microbes, rather than synthesized from scratch in a lab.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at TechCrunch.
Discussion
0 commentsMore from TechCrunch
